| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $17.7M | -20.5% | -42.2% |
| SG&A Expense | $7.2M | +1.4% | -9.5% |
| Operating Income | -$24.9M | +15.2% | +35.5% |
| Net Income | -$22.8M | +15.4% | +35.2% |
| EPS (Basic) | -$0.32 | +15.8% | +36.0% |
| EPS (Diluted) | -$0.32 | +15.8% | +36.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.0M | -1.0% | -48.2% |
| Short-term Investments | $160.7M | -9.1% | -24.6% |
| Current Assets | $201.1M | -8.3% | -30.5% |
| Total Assets | $211.5M | -8.1% | -29.8% |
| Current Liabilities | $11.3M | -1.8% | -8.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$64.5M | — | — |
| Capital Expenditures | $108K | — | — |
| Investing Cash Flow | $68.7M | — | — |
| Financing Cash Flow | $271K | — | — |
| Free Cash Flow | -$64.6M | — | — |
| $20.1M |
| -2.5% |
| -10.0% |
| Stockholders' Equity | $191.4M | -8.6% | -31.4% |